Ingrid C. McCall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ingrid C. McCall has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Brandon A. Berryhill
Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
2 shared publications - Bruce R. Levin
Department of Biology, Emory University
2 shared publications - Charles A. Parkos
Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
1 shared publication - Diarmaid Hughes
Department of Medical Biochemistry and Microbiology, Uppsala University , Uppsala
1 shared publication Dominique A. Weber
Epithelial Pathobiology Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322
1 shared publication- Douglas L. Huseby
Department of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University , Uppsala S-751 23
1 shared publication
Latest Publications
- Open Access
What the book of Lambda doesn’t tell us about temperate phages and lysogeny in the real world
The most significant difference between bacteriophages functionally and ecologically is whether they are purely lytic (virulent) or temperate. Virulent phages can only be transmitted horizontally by infection, most commonly with the death of their hosts. Temperate phages can also be transmitted horizontally, but upon infection of susceptible bacteria, their genomes can be incorporated into that of their host’s as a prophage and be transmitted vertically in the course of cell division by their lysogenic hosts. From what we know from studies with the temperate phage Lambda and other temperate phages, in laboratory culture, lysogenic bacteria are protected from killing by the phage coded for by their prophage by immunity; where upon infecting lysogens, the free temperate phage coded by their prophage are lost. Why are lysogens not also resistant as well as immune to the phage coded by their prophage since immunity does not confer protection against virulent phages? To address this question, we used a mathematical model and performed experiments with temperate and virulent mutants of the phage Lambda in laboratory culture. Our models predict and experiments confirm that selection would favor the evolution of resistant as well as immune lysogens, particularly if the environment includes virulent phage that share the same receptors as the temperate. To explore the validity and generality of this prediction, we examined ten lysogenic Escherichia coli from natural populations. All ten were capable of forming immune lysogens but their original hosts were resistant to the phage coded by their prophage. Significance Statement: This jointly theoretical and experimental study predicted that lysogenic bacteria, will be resistant as well as immune to the phage coded for by their prophage. All ten naturally occurring lysogenic Escherichia coli tested were resistant to the temperate phage coded for by their prophage.
Open AccessWhat the book of Lambda doesn’t tell us about temperate phages and lysogeny in the real world
The most significant difference between bacteriophages functionally and ecologically is whether they are purely lytic (virulent) or temperate. Virulent phages can only be transmitted horizontally by infection, most commonly with the death of their hosts. Temperate phages can also be transmitted horizontally, but upon infection of susceptible bacteria, their genomes can be incorporated into that of their host’s as a prophage and be transmitted vertically in the course of cell division by their lysogenic hosts. From what we know from studies with the temperate phage Lambda and other temperate phages, in laboratory culture, lysogenic bacteria are protected from killing by the phage coded for by their prophage by immunity; where upon infecting lysogens, the free temperate phage coded by their prophage are lost. Why are lysogens not also resistant as well as immune to the phage coded by their prophage since immunity does not confer protection against virulent phages? To address this question, we used a mathematical model and performed experiments with temperate and virulent mutants of the phage Lambda in laboratory culture. Our models predict and experiments confirm that selection would favor the evolution of resistant as well as immune lysogens, particularly if the environment includes virulent phage that share the same receptors as the temperate. To explore the validity and generality of this prediction, we examined ten lysogenic Escherichia coli from natural populations. All ten were capable of forming immune lysogens but their original hosts were resistant to the phage coded by their prophage. Significance Statement: This jointly theoretical and experimental study predicted that lysogenic bacteria, will be resistant as well as immune to the phage coded for by their prophage. All ten naturally occurring lysogenic Escherichia coli tested were resistant to the temperate phage coded for by their prophage.
- Open Access
- 9 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (10)
Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections
Significance: This study explores the potential of a phage, PYO Sa , for treating Staphylococcus aureus infections in combination with antibiotics. Population dynamic and genomic analysis identified a limitation and potential liability of using PYO Sa for therapy. Due to the production of potentially pathogenic atypical small colony variants, PYO Sa alone cannot eliminate S. aureus populations. However, we demonstrate that by following the administration of PYO Sa with bactericidal antibiotics, this limitation and potential liability can be addressed. The methods used in this investigation to explore the efficacy of combinations of PYO Sa and antibiotics for treating S. aureus infections can be employed to evaluate the clinical potential and facilitate the design of treatment protocols for any bacteria and phage that can be cultured in vitro.
- 9 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (10)
Open AccessEvaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections
Significance: This study explores the potential of a phage, PYO Sa , for treating Staphylococcus aureus infections in combination with antibiotics. Population dynamic and genomic analysis identified a limitation and potential liability of using PYO Sa for therapy. Due to the production of potentially pathogenic atypical small colony variants, PYO Sa alone cannot eliminate S. aureus populations. However, we demonstrate that by following the administration of PYO Sa with bactericidal antibiotics, this limitation and potential liability can be addressed. The methods used in this investigation to explore the efficacy of combinations of PYO Sa and antibiotics for treating S. aureus infections can be employed to evaluate the clinical potential and facilitate the design of treatment protocols for any bacteria and phage that can be cultured in vitro.
- Open Access
- 1 December 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (49) , 37953-37963
The Role of cis Dimerization of Signal Regulatory Protein α (SIRPα) in Binding to CD47
- 1 December 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (49) , 37953-37963
Open AccessThe Role of cis Dimerization of Signal Regulatory Protein α (SIRPα) in Binding to CD47